TNGX
Tango Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.93B
P/E Ratio
—
EPS
$-0.83
Beta
1.22
52W High
$28.41
52W Low
$1.91
50-Day MA
$22.08
200-Day MA
$12.62
Dividend Yield
—
Profit Margin
-188.10%
Forward P/E
—
PEG Ratio
—
About Tango Therapeutics Inc
Tango Therapeutics Inc. is a pioneering clinical-stage biotechnology company dedicated to transforming cancer treatment with its innovative focus on synthetic lethality and targeted therapies. The company's extensive pipeline features a range of promising drug candidates aimed at precision oncology, positioning it as a key player in the field. By forging strategic collaborations with leading academic institutions, Tango enhances its research capabilities and strengthens its commitment to addressing significant unmet needs in cancer care. Through its forward-thinking approach, Tango Therapeutics seeks to significantly improve patient outcomes and reshape treatment standards in oncology.
Fundamentals
| Revenue (TTM) | $56.99M |
| Gross Profit (TTM) | $-72.27M |
| EBITDA | $-115.41M |
| Operating Margin | -206.20% |
| Return on Equity | -38.40% |
| Return on Assets | -20.70% |
| Revenue/Share (TTM) | $0.46 |
| Book Value | $2.55 |
| Price-to-Book | 7.48 |
| Price-to-Sales (TTM) | 51.37 |
| EV/Revenue | 45.28 |
| EV/EBITDA | -0.91 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $144.65M |
| Float | $69.60M |
| % Insiders | 1.38% |
| % Institutions | 126.91% |
Historical Volatility
HV 10-Day
117.16%
HV 20-Day
103.06%
HV 30-Day
99.06%
HV 60-Day
101.42%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($31.90 target)
1
Strong Buy10
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026